Phase 3
Lifeomics technology, large-scale population cohort study and big data analysis platform are the elements for building China's precision medicine system. The new generation of high-throughput and high-coverage bio-omics technology with high-performance mass spectrometry as the core is booming, injecting continuous innovation into the research and translational applications of complex disease occurrence and development mechanisms, clinical multi-omics biomarker profiles.
In order to promote multidisciplinary and multi-field exchanges around precision medicine, the third issue of the "SciTalk Life Omics Mass Spectrometry Cloud Lecture" series of online events hosted by the Shanghai Institute of Clinical Bioinformatics will be held in August 2022 Held on the 31st. This meeting invited many domestic clinical experts and omics mass spectrometry application scientists to share the latest technological progress and clinical practice results. The event is co-organized by SCIEX China, Baiqu Biotechnology, AJEL Feinomei, and Xiwei Medical. Relevant application experts will also demonstrate new technologies for chromatography, mass spectrometry, and biological sample preprocessing to support the development of lifeomics and clinical scientific research.
Expert introduction
Professor Tang Huiru Professor
Fudan University
Distinguished professor of Fudan University, School of Life Sciences - Sun Yat-sen Hospital - Three-term professor of Human Phenome Research Institute. President of the Metabolomics Branch of the Chinese Biophysical Society and executive director of the Tumor Metabolism Branch of the Chinese Anti-Cancer Association. Winner of the National Science Fund for Distinguished Young Scholars, Chief Scientist of the National Key Research and Development Program of "Precision Medicine", National Candidate of the "New Century Talents Project", and enjoys special government subsidies from the State Council. He has been studying the structure and function of metabolites for 32 years, and is developing high-throughput ultra-sensitive metabolomics technology, metabolome and transcriptome / proteome /microbiome and other data integration technologies to study the occurrence and development of major diseases such as obesity. The basis of the metabolome. He has published more than 200 SCI papers such as Nature and PNAS, and has been approved for many international and Chinese invention patents.
Yintong Researcher
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Ph.D., researcher, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, head of the mass spectrometry platform of the National Center for Translational Medicine (Shanghai), main research directions include the pathogenesis of leukemia Multi-omics research; the interaction between hematopoietic stem cells and microenvironment , etc. He has won the Special Fellow Award from the American Society of Hematology and Lymphoma. At the end of 2015, he was introduced to Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine as the platform leader and project leader. He has successively presided over the National Natural Science Foundation general project, Shanghai Municipal Science and Technology Commission Pujiang Talent Plan, Shanghai Municipal Education Commission Gaofeng Plateau Jiaotong Medical "Double Hundred Talents" "Plan and Ruijin Hospital Broadcast Through projects such as the Ci Innovation Technology Launch Plan, 13 SCI papers with the first/ corresponding author were published in first-class journals such as Nature, Science, Blood, PNAS, JCI, etc., with a total impact factor of 190.486.
Zhong Chenchun Ph.D.
SCIEX China
graduated from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and received a doctorate in pharmacology in 2017. Currently working at SCIEX China Application Support Center, he is mainly responsible for application support in the fields of metabolomics and lipidomics related analysis. He has more than 10 years of research experience in mass spectrometry analysis.
Yuan Xiaofang Senior Product Manager
BIOTREE
graduated from Asia University in South Korea . His research direction is the application of microbial metabolomics in metabolic engineering. Focusing on the field of metabolomics, he is mainly engaged in project control and data analysis. He has rich experience in the field of microbial and plant metabolomics research.
Cloud Lecture Hall Introduction
life-omics technology, large-scale population cohort research and big data analysis platform are the main elements of building a precision medicine system. At present, a new generation of high-throughput quantitative life-omics technology with high-performance mass spectrometry as the core is booming, which provides opportunities for exploration of the occurrence and development mechanisms of complex diseases, clinical multi-omics biomarker spectrum research and the establishment of precise diagnosis and treatment systems. Precise solutions.
In order to promote multi-disciplinary and multi-field exchanges and discussions around precision medicine, it is hosted by the Shanghai Institute of Clinical Bioinformatics, the Genetic Testing Technology Branch of the Chinese Medical and Biotechnology Association, and the Translational Medicine Network, and is hosted by SCIEX China, Aijerfenomei The "SciTalk Lifeomics Mass Spectrometry Cloud Lecture Hall " series of academic activities co-organized by , Xinwei Medical and Xiwei Medical will officially kick off on March 10, 2022. This series of academic activities will invite many domestic clinical experts, basic research scientists and multi-omics mass spectrometry application scientists to share cutting-edge technological progress and clinical practice results. Through systematic sharing and discussion of new technologies in chromatography-mass spectrometry and biological sample preprocessing, Promote the development of bioomics and clinical scientific research.
SciTalk Cloud Lecture Phase 1: Respiratory Disease Research Progress and Metabolomics Mass Spectrometry New Technology
SciTalk Cloud Lecture Phase 2: Progress in Cancer Precision Diagnosis and Treatment Strategies and Mass Spectrometry Research Methods
END
